A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

In conclusion, rhTPO is a potentially safe and effective treatment choice for patients with ITP during pregnancy. Our work has paved the way for further study on the clinical application of rhTPO and other thrombopoietic agents for the management of ITP during pregnancy. This study is registered at www.clinicaltrials.gov as NCT02391272.

Source: Blood - August 31, 2017 Category: Hematology Authors: Kong, Z., Qin, P., Xiao, S., Zhou, H., Li, H., Yang, R., Liu, X., Luo, J., Li, Z., Ji, G., Cui, Z., Bai, Y., Wu, Y., Shao, L., Peng, J., Ma, J., Hou, M. Tags: Thrombocytopenia, Free Research Articles, Platelets and Thrombopoiesis, Clinical Trials and Observations Source Type: research